skyebioscience.com - SKYE Total Enterprise Value

Brandmark of Skye Bioscience, Inc. (SKYE)

Skye Bioscience, Inc. (SKYE) is a developer of synthetic cannabinoid-based drugs focusing on glaucoma therapy and weight management. The price action, where the indicator stands at -4.08, is based on the test results of the new CB1 molecule. Growth prospects are driven by entry into the metabolic drug segment and the probability of acquisition by market behemoths, provided there is strict control over medical research expenditures.

Skye Bioscience Inc. (SKYE) Total Company Value: for the period 11/23/2025 - 10/30/2026

Summary analytical data breakdowns for Skye Bioscience, Inc. (SKYE)

- market price and analyst price targets:
Stock Price Skye Bioscience Inc.|SKYE - Consensus Target
- issuer market value details:
Market Value Skye Bioscience|SKYE - Enterprise Value
- book capitalization data:
Net Asset Value per Share Skye Bioscience|SKYE - Company Book Value|Capitalization to Book Value Ratio skyebioscience.com|SKYE - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital Skye Bioscience, Inc.|SKYE - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital skyebioscience.com|SKYE - Company Aggregate Debts|Debt to Book Value Skye Bioscience|SKYE - Company Long-Term Debt|Short-Term Debt Skye Bioscience|Intermediate Coverage Ratio skyebioscience.com
- earnings and market multiples details:
SKYE - Net Profit
Summary company analytics:SKYE - Skye Bioscience Inc.
Original product of Skye Bioscience Inc.

The development of innovative obesity treatments drives the high value of Skye Bioscience, Inc. (SKYE) intellectual assets. An analysis of the total enterprise value allows for the determination of the company's actual acquisition cost by summing market capitalization and net debt, reflecting the business's fundamental foundation and the long-term investor consensus regarding the value of its scientific and technological potential.

Competitors of Skye Bioscience, Inc. (SKYE)

Enterprise Value Indivior plc INDV|COLL: Real Price to Acquire Entire Company|Total Enterprise Value Cronos Corp|CGC: Enterprise Value|Total Enterprise Value hightideinc.com (HITI)|Total Company Value Aurora Cannabis, Inc.|Business Value ACHV (Achieve Life Sciences Inc.)|Enterprise Value ANEB|Enterprise Value intercure.co (INCR)|Total Company Value Nutriband NTRB|Value Adjusted for Debt and Cash NSRX|IGC Pharma Inc - Enterprise Value|MIRA Pharmaceuticals (MIRA) - Real Price to Acquire Entire Company|Flora Growth Corporation (FLGC) - Total Company Value|Total Enterprise Value IM Cannabis (IMCC)|Real Price to Acquire Entire Company ADIL|ARTL: Value Adjusted for Debt and Cash|Enterprise Value ENSC|TTNP: Full Business Value|Enterprise Value GNLN (Greenlane Holdings Inc)|Enterprise Value InMed INM|AKAN - Total Company Value|Value Adjusted for Debt and Cash ENVB (enveric.com)|brightgreen.us (BGXX) - Total Company Value|Real Price to Acquire Entire Company Hempacco Co Inc.